Serge Korjian

List of Publications by Year in descending order

49 papers	2,444 citations	471477 17 h-index	223791 46 g-index
49 all docs	49 docs citations	49 times ranked	4092 citing authors

#	Article	IF	Citations
1	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. New England Journal of Medicine, 2016, 375, 2423-2434.	27.0	1,265
2	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction. Circulation, 2016, 134, 1918-1930.	1.6	148
3	EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. European Heart Journal, 2016, 37, 1296.1-1303.	2.2	112
4	The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. TH Open, 2017, 01, e56-e65.	1.4	94
5	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation, 2017, 135, 323-333.	1.6	86
6	d-Dimer elevation and adverse outcomes. Journal of Thrombosis and Thrombolysis, 2015, 39, 55-59.	2.1	75
7	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients. Circulation, 2017, 135, 648-655.	1.6	61
8	Vitamin K2 supplementation and arterial stiffness among renal transplant recipientsâ€”a single-arm, single-center clinical trial. Journal of the American Society of Hypertension, 2017, 11, 589-597.	2.3	49
9	The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous) Tj ETQq1 1 0.784314 rgBT /Ove Journal, 2017, 185, 93-100.	2.7	48
10	Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. Thrombosis and Haemostasis, 2018, 118, 2046-2052.	3.4	48
11	Comparison of Fatal or Irreversible Events With Extendedâ€Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. Journal of the American Heart Association, 2017, 6, .	3.7	40
12	Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment. International Urology and Nephrology, 2018, 50, 1075-1083.	1.4	30
13	Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. American Heart Journal, 2016, 180, 22-28.	2.7	25
14	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. American Heart Journal, 2019, 208, 81-90.	2.7	25
15	The Impact of the COVID-19 Pandemic on Cardiovascular Fellows-in-Training. Journal of the American College of Cardiology, 2020, 76, 871-875.	2.8	24
16	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f50-f60.	3.0	24
17	Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 774418.	2.4	23
18	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. American Heart Journal, 2018, 198, 84-90.	2.7	19

#	Article	IF	Citations
19	Medical education in a foreign language and history-taking in the native language in Lebanon â€“ a nationwide survey. BMC Medical Education, 2016, 16, 298.	2.4	17
20	Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). American Journal of Cardiology, 2018, 122, 1896-1901.	1.6	17
21	Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis. Circulation: Cardiovascular Interventions, 2016, 9, e003114.	3.9	14
22	When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. American Heart Journal, 2017, 189, 1-8.	2.7	14
23	Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. Journal of Thrombosis and Thrombolysis, 2018, 45, 1-8.	2.1	14
24	Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity. Journal of the American Heart Association, 2022, 11, e024754.	3.7	13
25	Etiology of End-Stage Renal Disease and Arterial Stiffness among Hemodialysis Patients. BioMed Research International, 2017, 2017, 1-6.	1.9	12
26	Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 186-193.	1.0	12
27	Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. Thrombosis and Haemostasis, 2021, 121, 1562-1573.	3.4	12
28	Change in Pulse Wave Velocity and Shortâ€Term Development of Cardiovascular Events in the Hemodialysis Population. Journal of Clinical Hypertension, 2016, 18, 857-863.	2.0	11
29	Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. Expert Review of Cardiovascular Therapy, 2017, 15, 237-245.	1.5	11
30	N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. Journal of Thrombosis and Thrombolysis, 2017, 44, 457-465.	2.1	11
31	Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Postâ€Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACSâ€TIMI 46 and ATLAS ACS 2â€TIMI 51. Journal of the American Heart Association, 2019, 8, .	3.7	10
32	Vitamin K2 Status and Arterial Stiffness Among Untreated Migraine Patients: A Caseâ€Control Study. Headache, 2020, 60, 589-599.	3.9	10
33	Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 227-232.	2.0	9
34	Renal Function Decline in Recipients and Donors of Kidney Grafts: Role of Aortic Stiffness. American Journal of Nephrology, 2015, 41, 57-65.	3.1	8
35	Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial). American Journal of Cardiology, 2016, 118, 625-631.	1.6	8
36	Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. TH Open, 2018, 02, e16-e24.	1.4	8

#	Article	IF	Citations
37	ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future. Current Atherosclerosis Reports, 2022, 24, 585-597.	4.8	8
38	Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. Circulation, 2019, 139, 1234-1236.	1.6	7
39	Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). American Journal of Cardiology, 2019, 123, 355-360.	1.6	6
40	Digital technologies and the democratization of clinical research: Social media, wearables, and artificial intelligence. Contemporary Clinical Trials, 2022, 117, 106767.	1.8	6
41	Early and late recurrent cardiovascular events among highâ€risk patients with an acute coronary syndrome: Metaâ€analysis of phase III studies and implications on trial design. Clinical Cardiology, 2022, , .	1.8	3
42	Pheochromocytoma Presenting as Partial HELLP Syndrome. Case Reports in Obstetrics and Gynecology, 2015, 2015, 1-3.	0.3	2
43	Collateral Circulation in ChronicÂTotalÂOcclusions. JACC: Cardiovascular Interventions, 2017, 10, 915-917.	2.9	2
44	Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. TH Open, 2019, 03, e103-e108.	1.4	1
45	Dual Antiplatelet Therapy Following PCI for NSTEMI. Journal of the American College of Cardiology, 2020, 76, 2447-2449.	2.8	1
46	Patterns of Recovery in Cardiovascular Care after the COVID-19 Pandemic Surge. American Journal of the Medical Sciences, 2021, , .	1.1	1
47	Dual Pathway Therapy for Secondary Prevention Following Acute Coronary Syndrome. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	0
48	Outcome Of Bone Marrow Transplantation In Lebanese Children With Î²-Thalassemia Major. Blood, 2013, 122, 5505-5505.	1.4	0
49	Organ procurement: should we teach undergraduate medical and nursing students?. Experimental and Clinical Transplantation, 2015, 13 Suppl 1, 55-8.	0.2	0